Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 10/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470278 | 0.89 | KCNA5 (0.54) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL4023312 | 0.88 | KCNA5 (0.47) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL4354871 | 0.85 | KCNA5 (0.45) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL3310850 | 0.85 | KCNA5 (0.54) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL12863383 | 0.82 | CXCR3 (0.57) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL3308573 | 0.82 | KCNA5 (0.51) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL4243043 | 0.82 | CXCR3 (0.50) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL2473634 | 0.81 | KCNA5 (0.50) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL3312841 | 0.80 | KCNA5 (0.48) | PTPN1KCNA5CXCR3HDAC3HDAC11 | |
| SCHEMBL4069164 | 0.77 | CXCR3 (0.49) | PTPN1KCNA5CXCR3HDAC3HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244648-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-7022717-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | BRIDGER GARY J | 2006-03-30 | — | — | US | disclosed |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2004-05-27 | — | — | US | disclosed |
| US-6667320-B2 | For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV) | ANORMED (CA) | 2003-12-23 | — | — | US | disclosed |
| EP-1244648-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2002-06-20 | — | — | US | disclosed |
| WO-2001044229-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | PTPN1 4214/4885KCNA5 3461/4885CXCR3 7/4885 |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | PTPN1 4214/4885KCNA5 3461/4885CXCR3 7/4885 |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | PTPN1 4214/4885KCNA5 3461/4885CXCR3 7/4885 |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | PTPN1 4214/4885KCNA5 3461/4885CXCR3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.